Company: IPGP
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001111928-25-000069
Chunk: 30

Company: IPG PHOTONICS CORP
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 30
---
 $47,209 Provision for warranty accrual1,742 1,680 Warranty claims(3,779)(4,568)Foreign currency translation801 (687)Balance, end of period$33,116 $43,634 Accrued warranty reported in the accompanying Condensed Consolidated Financial Statements as of March 31, 2025 and December 31, 2024 consist of $20,492 and $21,398 in accrued expenses and other current liabilities, respectively, and $12,624 and $12,954 in other long-term liabilities and deferred income taxes, respectively.

10. FINANCING ARRANGEMENTS

Revolving Line of Credit Facilities:The Company maintains a $75,000 U.S. revolving line of credit, which is available to certain foreign subsidiaries and allows for borrowings in the local currencies of those subsidiaries. At March 31, 2025 and December 31, 2024, there were no amounts drawn on the U.S. line-of-credit, and there were $2,144 and $2,103, respectively, of guarantees issued against the facility, which reduce the amount of the facility available to draw. After providing for the guarantees used, the remaining availability under this line was $72,856 at March 31, 2025. In addition, the Company maintains Euro lines of credit facilities with a total principal amount of €6,500 ($7,033 and $6,751 as of March 31, 2025 and December 31, 2024, respectively), which are available to certain European subsidiaries. At March 31, 2025 and December 31, 2024, there were no amounts drawn on the 

11

Table of ContentsIPG PHOTONICS CORPORATIONNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)(In thousands, except share and per share data)

Euro lines of credit, and there were $1,505 and $1,533, respectively, of guarantees issued against the facility, which reduce the amount of the facility available to draw.

11. COMMITMENTS AND CONTINGENCIES

From time to time, the Company may be involved in legal disputes and other proceedings in the ordinary course of its business. These matters may include allegations of infringement of intellectual property, commercial disputes and employment matters. As of March 31, 2025 and through the filing date of these Condensed Consolidated Financial Statements, the